Wednesday, April 1, 2020

Novartis scraps sale of assets to Aurobindo Pharma after failing to get FTC nod

Novartis scraps sale of assets to Aurobindo Pharma after failing to get FTC nod Novartis said the decision to terminate the sale of Sandoz US#39;s generic oral solids and dermatology businesses was taken after the companies did not get approval from the U.S. Federal Trade Commission within anticipated timelines.

from Moneycontrol Business News https://ift.tt/2X3yjLJ
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

A 'non-event Budget' for stock market: Is that good news for Nifty which fell 1,000 points in January?

As Budget 2026 approaches, analysts expect a low-impact event for equities amid muted expectations. With Nifty already down sharply in Janua...